Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.

The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.

Ansa Biotechnologies, a California-based start-up focused on updating DNA synthesis technologies, is advancing toward the launch of a customizable DNA synthesis service, stemming from the development of a novel synthesis method.

Researchers have been working to develop approaches to curing Type 1 diabetes by transplanting healthy islet cells into the pancreas. Investigators at Northwestern University have developed a technique to make the immunomodulation effect of immunosuppressive drugs more effective.

Researchers in Singapore developed the world’s largest and highest-resolution atlas of gastric cancer.

Investigators at Washington University School of Medicine in St. Louis identified a compound that can help sensory neurons in the central nervous system to heal.

The mission of new startup Colossal, which has raised $15 million to date, is to genetically reengineer a cold-resistant elephant with all the core biological traits of the extinct woolly mammoth.

Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.

Shape Therapeutics generated $112 million from a recent Series B financing round the Seattle biotechnology firm co-led with Decheng Capital and Breton Capital.

Intellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically.